Schedules Conference Call for December 30, 2016 at 9:00 am ET
IRVINE, Calif., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today provided an update on the previously announced temporary hold on shipments of its AFX® and AFX2® Endovascular AAA Systems. Based upon positive testing results, the company has removed the temporary hold on all sizes of the AFX Endovascular AAA System and some sizes of the AFX2 Endovascular AAA System, which will allow these products to be shipped to customers and used in procedures, effective immediately. Testing and process improvements for the remaining sizes of the AFX2 system are on-going.
The Company also announced that it will host a conference call and webcast on Friday, December 30, 2016 at 9:00 am ET to provide an update on the business and more details on AFX.
Conference Call and Webcast Information
Endologix's management will host a conference call today at 9:00 am ET. To participate via telephone please call 1-888-801-6492 from the U.S. or 1-913-312-6665 from outside the U.S. (conference ID# 7972936). A telephone replay will be available for seven days following the completion of the call by dialing 1-844-512-2921 from the U.S. or 1-412-317-6671 from outside the U.S., and entering pin number 7972936. The conference call will be broadcast live over the Internet at www.endologix.com. After the live webcast, a webcast replay of the call and a transcript of the call will be available online from the investor relations page of Endologix's website through December 30, 2017.
About Endologix, Inc.
Endologix, Inc., develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the United States. Additional information can be found on Endologix's website at www.endologix.com.
Forward-Looking Statements
This communication includes statements that may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to the temporary hold on, and resumption of shipments of AFX and AFX2 systems, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including further product inspection findings and additional regulatory requirements. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Endologix undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Endologix's Annual Report on Form 10-K for the year ended December 31, 2015, and Endologix's subsequent filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.